The FDA has granted fast track status to 67Cu-SAR-bisPSMA for metastatic prostate cancer that is resistant to hormone therapy ...
If you purchased or acquired securities in ESSA Pharma between December 12, 2023 and October 31, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at ...
Combining an existing small-molecule protein therapy called tumor necrosis factor related apoptosis-inducing ligand (TRAIL) ...
Taxpayers spent $74.5 million to help develop the prostate cancer-fighting drug Xtandi, but its sky-high sticker price is limiting access to patients and siphoning money away from Medicaid, according ...
Interesting Engineering on MSN46m
Researchers use focused ultrasound to shrink prostate tumors, no surgery neededResearchers from Rice University and Vanderbilt University have made significant advancements in the fight against prostate ...
Bernstam, MD, discusses updated findings from the phase 1 TROPION-PanTumor01 study of datopotamab deruxtecan-dlnk in heavily ...
Tremfya could become the first IL-23 inhibitor with fully subcutaneous induction and maintenance options in the treatment of ...
A new study shows that neutralising GDF-15 restores immune response in advanced cancers resistant to PD-1 blockade.
Researchers explored how Pluvicto is used in the community and academic settings and when given by oncologists or urologists.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback